Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Germany”

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaRecruiting
NCT06106945Phase 1, Phase 2Updated Aug 19, 2026
Sponsor: AstraZeneca
Multiple Myeloma
United States, Australia, Brazil, Canada, China +4 more
MiCLASP Post Market Clinical Follow-Up (PMCF) StudyActive Not Recruiting
NCT04430075N/AUpdated Aug 19, 2026
Sponsor: Edwards Lifesciences
Mitral Regurgitation · Mitral Insufficiency
Austria, Germany, Greece, Italy, Netherlands +4 more
Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis HouseholdsRecruiting
NCT07369414N/AUpdated Aug 19, 2026
Sponsor: Research Center Borstel
Cystic Fibrosis (CF) · Mucoviscidosis · Non-Tuberculous Mycobacteria · Mycobacterium Abscessus Infection
Germany
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa ColonizationRecruiting
NCT07088926Phase 2Updated Aug 18, 2026
Sponsor: AstraZeneca
Bronchiectasis With Pseudomonas Aeruginosa Colonization
United States, Argentina, Australia, Belgium, Brazil +20 more
Prehabilitation in Childhood Soft Tissue or Bone SarcomasActive Not Recruiting
NCT06743958NAUpdated Aug 18, 2026
Sponsor: Technical University of Munich
Soft Tissue Sarcoma of the Lower Extremity · Bone Tumor of the Lower Extremity · Childhood and Adolescent Cancer
Germany
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth SpectrumActive Not Recruiting
NCT04589650Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
United States, Canada, China, France, Germany +7 more
Evaluation of Integration Success and Crestal Bone Preservation Biomet 3i's T3 Implant SystemCompleted
NCT02161874NAUpdated Aug 18, 2026
Sponsor: ZimVie
Partial Edentulism · Tooth Disease
Belgium, France, Germany, United Kingdom
AI Based Muscular Ultrasound to Assess Intensive Care Unit-acquired WeaknessCompleted
NCT06765551N/AUpdated Aug 18, 2026
Sponsor: Jena University Hospital
Intensive Care Unit-acquired Weakness · Artifical Intelligence · Ultrasound
Germany
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)Recruiting
NCT07366034Phase 3Updated Aug 18, 2026
Sponsor: Boehringer Ingelheim
Fibrosing Interstitial Lung Disease
United States, Argentina, Australia, Belgium, Brazil +17 more
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)Recruiting
NCT06858579Phase 3Updated Aug 18, 2026
Sponsor: Dianthus Therapeutics
Chronic Inflammatory Demyelinating Polyneuropathy
United States, Argentina, Australia, Belgium, Brazil +24 more
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)Recruiting
NCT06780111Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Merck Sharp & Dohme LLC
Esophageal Squamous Cell Carcinoma
United States, Brazil, Chile, China, Czechia +10 more
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaNot Yet Recruiting
NCT07763171Phase 3Updated Aug 18, 2026
Sponsor: Gruppo Oncologico del Nord-Ovest
Gastroesophageal Adenocarcinoma
Germany, Italy, Spain
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityRecruiting
NCT07567001Phase 3Updated Aug 18, 2026
Sponsor: Novo Nordisk A/S
Obesity · Heart Failure
United States, Argentina, Australia, Brazil, Bulgaria +22 more
Venetoclax After TKI to Target Persisting Stem Cells in CMLCompleted
NCT05701215Phase 2Updated Aug 18, 2026
Sponsor: Thomas Ernst, PD Dr. med.
Chronic Myeloid Leukemia
Germany
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral SclerosisRecruiting
NCT07660614Phase 1, Phase 2Updated Aug 18, 2026
Sponsor: Leal Therapeutics, Inc
Amyotrophic Lateral Sclerosis
Germany, Italy, Netherlands, Sweden
Dabrafenib and/or Trametinib Rollover StudyRecruiting
NCT03340506Phase 4Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Melanoma · Non Small Cell Lung Cancer · Solid Tumor · Rare Cancers
United States, Argentina, Austria, China, Denmark +7 more
The Erlanger Stroke Project is an Ongoing Prospective Population-based Stroke Registry in Germany, Including All Hospitalized and Nonhospitalized Patients With Stroke in the City of Erlangen (120.000 Inhabitants).Recruiting
NCT07771335N/AUpdated Aug 18, 2026
Sponsor: University of Erlangen-Nürnberg Medical School
Intracerebral Haemorrhage (ICH) · Cerebral Infarction · Cerebral Infarction Due to Thrombosis of Cerebral Arteries · Cerebral Infarction Due to Embolism of Cerebral Arteries
Germany
Frontline Asciminib Combination in Chronic Phase CMLActive Not Recruiting
NCT03906292Phase 2Updated Aug 18, 2026
Sponsor: University of Jena
Chronic Myeloid Leukemia
Germany
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active Not Recruiting
NCT07047118Phase 2Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Prostatic Cancer, Castration-Resistant
United States, Australia, Austria, Canada, China +10 more
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruiting
NCT06743126Phase 3Updated Aug 18, 2026
Sponsor: Immatics US, Inc.
Melanoma, Cutaneous Malignant
United States, Canada, France, Germany, Netherlands +1 more
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.Recruiting
NCT05948943Phase 2, Phase 3Updated Aug 18, 2026
Sponsor: Novartis Pharmaceuticals
Lymphatic Malformations
United States, Argentina, Australia, Belgium, Czechia +7 more
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruiting
NCT07415031Phase 2Updated Aug 18, 2026
Sponsor: Mirati Therapeutics Inc.
Solid Tumors
United States, Australia, Belgium, Canada, China +15 more
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive Not Recruiting
NCT03732820Phase 3Updated Aug 18, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer
United States, Australia, Belgium, Brazil, Canada +12 more
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1Recruiting
NCT07486934Phase 3Updated Aug 18, 2026
Sponsor: Dyne Therapeutics
Myotonic Dystrophy Type 1 (DM1) · DM1 · Myotonic Dystrophy · Steinert Disease
United States, Belgium, Denmark, France, Germany +5 more
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Recruiting
NCT03486873Phase 3Updated Aug 18, 2026
Sponsor: Merck Sharp & Dohme LLC
Solid Tumors · Hematologic Malignancies
United States, Argentina, Australia, Austria, Belgium +46 more

Previous page Next page